GILEAD SCIENCES, INC. (GILD) Form 8-K — Oct 29, 2026
Gilead reported strong Q3 2026 results, with total product sales up 13% to $8.3 billion and product sales excluding Veklury up 16% to $8.2 billion — its strongest base business growth in more than a decade, led by 18% HIV growth and a near-doubling of HIV prevention sales. Non-GAAP diluted EPS was $2.55 versus $2.47 a year ago, while GAAP EPS fell to $1.94 from $2.43 due to equity securities losses and higher operating expenses and taxes. The company raised full-year 2026 product sales guidance to $31.0-31.3 billion, a cumulative $1.6 billion increase since the start of 2026.
Key figures
- Eps
- 1.94
- Revenue
- 8300000000
- Guidance
- FY2026 product sales $31.0-31.3B (raised from $30.1-30.4B); non-GAAP diluted loss per share $(1.20)-$(0.85), including ~$9.88 of IPR&D charges from $12.4B in Arcellx, Tubulis, Ouro Medicines and PepStar transactions
- Net Income
- 2429000000
- Revenue Yoy
- 7% total revenues; product sales +13%
- Total Assets
- 51408000000
- Cash Position
- 6437000000
- Shares Outstanding
- 1241000000
- Hiv Sales
- 6249000000
- Hiv Growth
- 18%
- Descovy Sales
- 1046000000
- Veklury Sales
- 86000000
- Biktarvy Sales
- 4059000000
- Trodelvy Sales
- 506000000
- Free Cash Flow Q3
- 4798000000
- Non Gaa PDiluted EPS
- 2.55
- Operating Cash Flow Q3
- 5035000000
- Product Gross Margin GAAP
- 81.0%
- Non Gaa PDiluted EPS prior
- 2.47
- Quarterly Dividend Per Share
- 0.82
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.